Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 9/20 | 0.42 |
| ▸ | DRD2 | P14416 | 8/20 | 0.42 |
| ▸ | DRD5 | P21918 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041630 | 0.81 | ALDH1A1 (0.43) | PARP1PARP2DRD3DRD2DRD4 | |
| SCHEMBL13041625 | 0.80 | ALDH1A1 (0.39) | PARP1 | |
| SCHEMBL13041643 | 0.78 | ALOX15 (0.36) | DRD3DRD2 | |
| SCHEMBL13041635 | 0.78 | PARP1 (0.43) | PARP1PARP2 | |
| SCHEMBL13041634 | 0.78 | PARP1 (0.43) | PARP1PARP2DRD3DRD2DRD4 | |
| SCHEMBL13041639 | 0.77 | PARP1 (0.43) | PARP1DRD3CHRM2CHRM1DRD1 | |
| SCHEMBL13041631 | 0.75 | ENPP2 (0.51) | PARP1DRD3 | |
| SCHEMBL13041641 | 0.74 | BRD4 (0.41) | PARP1HTR1A | |
| SCHEMBL13041644 | 0.73 | OPRL1 (0.42) | DRD2SIGMAR1 | |
| SCHEMBL13015326 | 0.73 | BRD4 (0.42) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | PARP1 3310/4885PARP2 4134/4885DRD3 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.